SCHEMBL7188499

SCHEMBL7188499

CCCCOc1ccc(PC(=O)c2c(OC)cc(OC)cc2OC)cc1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.44
KMT2A Q03164 2/20 0.42
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
PLA2G4B P0C869 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
PDE4A P27815 1/20 0.41
HIF1A Q16665 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181380 0.97 PLA2G4B (0.46) AHRTHRATHRBPLA2G4BTSHR
SCHEMBL7187543 0.96 PLA2G4B (0.47) THRATHRBPLA2G4BTSHRNR5A1
SCHEMBL7189363 0.95 SLC5A1 (0.43) KMT2AGAALMNACYP2D6LTA4H
SCHEMBL7175855 0.90 KMT2A (0.41) KMT2ASMN1; SMN2LMNACYP1A2CYP2D6
SCHEMBL7183427 0.90 MAPT (0.45) AHRKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL7177848 0.89 APP (0.43) KMT2ATHRASMN1; SMN2LMNATSHR
SCHEMBL7187607 0.88 SMN1; SMN2 (0.46) SMN1; SMN2LMNAKDM4ECYP1A2CYP2D6
SCHEMBL7186646 0.86 MAPK1 (0.46) KMT2ATHRBGAASMN1; SMN2LMNA
SCHEMBL7187509 0.86 TDP1 (0.44) KMT2ALMNATSHRCYP2D6HDAC3
SCHEMBL7186732 0.86 KMT2A (0.52) KMT2AMEN1GAASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 AHR 770/4885KMT2A 1586/4885THRA 1901/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 AHR 713/4885KMT2A 956/4885THRA 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.